An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This study is a multicentre, open label, non-comparative, two stage phase II trial to assess
the activity of ZD1839 (IRESSA) in patients with malignant mesothelioma. Patients will
receive trial treatment as first-line therapy, administered continuously once daily until the
completion of six 4-week cycles of treatment, disease progression, unacceptable toxicity or
withdrawal of consent. Patients continuing to show evidence of response, disease
stabilization or clinical benefit from ZD1839 may continue to receive therapy beyond
completion of the trail.